Canada markets closed

Mind Medicine (MindMed) Inc. (MNMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.4500+0.0100 (+0.41%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.4400
Open2.4800
Bid2.4300 x 21500
Ask2.4900 x 40000
Day's Range2.4100 - 2.4800
52 Week Range0.3800 - 5.7700
Volume4,991,459
Avg. Volume4,869,687
Market Cap901.713M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.1660
Earnings DateNov. 11, 2021 - Nov. 15, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
  • CNW Group

    MindMed to Present at H.C. Wainwright 23rd Annual Global Investment Conference

    Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Robert Barrow, Chief Executive Officer of MindMed, will present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. Members of management will also be available to speak with institutional investors in one-on-one virtual meetings throughout the conference.

  • CNW Group

    MindMed to Attend 8th Annual "Mobile in Clinical Trials" Conference

    Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its Chief Medical Officer, Daniel R. Karlin, MD MA, will co-chair the 8th annual Mobile in Clinical Trials Conference, which will be held virtually on September 27, 2021 and is a partner program to the 2021 DPharm Conference.

  • CNW Group

    MindMed and BioXcel Therapeutics Publish an International Patent Application Describing a System for Identifying Agitation Episodes

    MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, and BioXcel Therapeutics, Inc. ("BioXcel"), a leading clinical-stage biopharmaceutical company, announce the publication of BioXcel's International Patent Application No. PCT/US2020/051256 (published as WO2021055595) for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour. The disclosure provides a method for mea